3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
59
Gastrointestinal Stromal Tumors
22
Neoplasms
18
Breast Neoplasms
16
Kidney Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Carcinoma
7
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Stomach Neoplasms
4
Neuroendocrine Tumors
4
Kidney Diseases
4
Gastrointestinal Neoplasms
4
Clear-cell metastatic renal cell carcinoma
4
Carcinoma, Hepatocellular
4
Adenoma, Islet Cell
4
Prostatic Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Pancreatic Neoplasms
2
Lung Neoplasms
2
Financial Stress
2
Urothelial Cancer
1
Urologic Diseases
1
Thyroid Neoplasms
1
Somatostatinoma
1
Solid Tumors
1
Solid Tumor
1
Primary hyperoxaluria type 2
1
Patient Preference
1
Interventions
pertuzumab
1
pazopanib
1
decitabine and cedazuridine drug combination
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Radiotherapy
1
Opdualag
1
Nivolumab
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Patient Preference
×
Sunitinib
×
Clear all
NCT01064310
2017-04-17
PISCES
Novartis
Phase 3
Completed
169 enrolled
16 charts